(S)-5-Hydroxy-4-{(S)-1-hydroxy-2-[(1S,2S,5R,8aR)-1,2,5-trimethyl-5-(4-methyl-pent-4-enyl)-1,2,3,5,6,7,8,8a-octahydro-naphthalen-1-yl]-ethyl}-5H-furan-2-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (S)-5-Hydroxy-4-{(S)-1-hydroxy-2-[(1S,2S,5R,8aR)-1,2,5-trimethyl-5-(4-methyl-pent-4-enyl)-1,2,3,5,6,7,8,8a-octahydro-naphthalen-1-yl]-ethyl}-5H-furan-2-one
• 英文别名: (2S)-3-[(1S)-2-[(1S,2S,5R,8aR)-1,2,5-trimethyl-5-(4-methylpent-4-enyl)-2,3,6,7,8,8a-hexahydronaphthalen-1-yl]-1-hydroxyethyl]-2-hydroxy-2H-furan-5-one
• 化学式: C₂₅H₃₈O₄
• 分子量: 402.574
• InChiKey: JOYRNJIWPUZFBJ-LAXAASGQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  ethyl 5-(triisopropylsiloxy)pent-2-ynoate 在 4-二甲氨基吡啶 、 copper(l) iodide 、 N-甲基吲哚酮 、 四丙基高钌酸铵 、 amberlyst-15 、 四甲基乙二胺 、 4 A molecular sieve 、 四丁基氟化铵 、 甲基锂 、 二甲基二环氧乙烷 、 二氯乙基铝 、 三乙基硼氢化锂 、 臭氧 、 乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 乙醚 、 二氯甲烷 、 叔丁醇 为溶剂， 反应 2.5h， 生成 (S)-5-Hydroxy-4-{(S)-1-hydroxy-2-[(1S,2S,5R,8aR)-1,2,5-trimethyl-5-(4-methyl-pent-4-enyl)-1,2,3,5,6,7,8,8a-octahydro-naphthalen-1-yl]-ethyl}-5H-furan-2-one
  参考文献：
  名称：

  Total Synthesis of (+)-Dysidiolide

  摘要：

  DOI：

  10.1021/jo972208h

文献信息

• Cdc25 photophatase inhibitors
  申请人：——

  公开号：US20040034103A1

  公开（公告）日：2004-02-19

  The invention concerns novel cdc25 phosphatase inhibitors, and in particular cdc25-C, which correspond to the general formula (I) wherein: A represents a carbocyclic aryl radical optionally substituted 1 to 3 times by one or more radicals independently selected among a halogen atom and an alkyl, hydroxy, alkoxy, alkylthio or NR 1 R 2 radical wherein R 1 and R 2 represent a hydrogen atom or an alkyl radical or R 1 and R 2 form together with the nitrogen atom a heterocycle of 4 to 7 members comprising 1 to 2 heteroatoms, the members required to complete the heterocycle being selected independently among the CR 3 R 4 —, —O—, —S and NR 5 -radicals, R 3 and R 4 representing independently each time they are involved a hydrogen atom or an alkyl, hydroxy, alkoxy, amino, alkylamino or dialkylamino radical, and R 5 representing independently each time it is involved a hydrogen atom or an alkyl radical, or A represents a phenyl radical substituted by a phenyl radical optionally substituted 1 to 3 times by one or more radicals selected independently among a halogen atom and an alkyl, hydroxy, alkoxy, alkylthio or NR 1 R 2 radical wherein R 1 and R 2 represent a hydrogen atom or an alkyl radical; B represents a —(CH 2 ) i —(CO)— or —NH—CO—(CH 2 ) n or —(CH 2 ) p and i and n being integers from 0 to 2 and p being an integer from 0 to 1; W represents a hydrogen atom or an alkyl radical; X represents a —(CH 2 ) q — or (CH 2 ) j —CO—(CH 2 ) r —, q being an integer from 1 to 4 and j and r being integers from 0 to 6; Y represents in particular a nitrophenyl, aminophenyl, alkylaminophenyl or dialkylaminophenyl radical or the radical (T). 1

  该发明涉及新型cdc25磷酸酶抑制剂，特别是cdc25-C，其对应于一般式(I)，其中：A代表一个通过卤原子、烷基、羟基、烷氧基、烷基硫基或NR1R2基团中独立选择的一个或多个基团1至3次取代的碳环芳基，其中R1和R2分别表示氢原子或烷基基团，或者R1和R2与氮原子一起形成包括1至2个杂原子的4至7个成员的杂环，用于完成杂环的成员独立选择于CR3R4—、—O—、—S和NR5基团中，其中R3和R4在涉及时分别表示氢原子或烷基、羟基、烷氧基、氨基、烷基氨基或二烷基氨基基团，R5在涉及时表示氢原子或烷基基团，或者A代表一个苯基基团，该苯基基团通过一个或多个基团1至3次独立选择的卤原子和烷基、羟基、烷氧基、烷基硫基或NR1R2基团取代；B代表一个—(CH2)i—(CO)—或—NH—CO—(CH2)n或—(CH2)p的基团，其中i和n为0至2的整数，p为0至1的整数；W代表氢原子或烷基基团；X代表一个—(CH2)q—或(CH2)j—CO—(CH2)r—的基团，其中q为1至4的整数，j和r为0至6的整数；Y特别代表一个硝基苯基、氨基苯基、烷基氨基苯基或二烷基氨基苯基基团或基团(T)。
• CDC25 inhibitors
  申请人：InterMed Discovery GmbH

  公开号：EP2130831A1

  公开（公告）日：2009-12-09

  The invention relates to pyridoquinolones, their synthesis and pharmaceutical use. The pyridoquinolones are useful as CDC25 inhibitors.

  本发明涉及吡啶并喹啉酮及其合成和药物用途。所述吡啶并喹啉酮作为CDC25抑制剂具有应用价值。
• Inhibitors of Cdc25 phosphatases
  申请人：Prevost Gregoire

  公开号：US20060154933A1

  公开（公告）日：2006-07-13

  A method of inhibiting cdc25 phosphatases in warm-blooded animals comprising administering to warm-blooded animals in need thereof an effective amount of a compound of the formula wherein the substituents are defined as in the specification.

  抑制温血动物cdc25磷酸酯酶的一种方法，包括向需要该方法的温血动物施用有效量的以下化合物：其中取代基的定义如规范中所述。
• Inhibitors of cdc25 phosphatases
  申请人：Prevost Gregoire

  公开号：US20060235027A1

  公开（公告）日：2006-10-19

  A method of inhibiting cdc25 phosphatases in warm-blooded animals comprising administering to warm-blooded animals in need thereof an effective amount of a compound of the formula wherein the substituents are defined as in the specification.

  抑制温血动物中cdc25磷酸酶的方法，包括向需要该方法的温血动物施用一种有效量的化合物，该化合物的公式如下：其中取代基的定义如规范中所述。
• DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS
  申请人：Odermatt Alex

  公开号：US20090062401A1

  公开（公告）日：2009-03-05

  The present invention relates to compounds having a decaline scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said decaline-derived compounds can be used for prophylaxsis and/or treatment of diabetes mellitus type I, diabetes mellitus type II, tuberculosis and other infectious diseases, proliferative diseases, cancer, neurodegenerative diseases, obesity, cognitive dysfunctions and metabolic syndromes.

  本发明涉及具有十二环骨架的化合物，这些化合物的药学上可接受的盐以及含有这些化合物之一的药物组合物，该组合物还包含药学上可接受的载体、赋形剂和/或稀释剂。所述的十二环衍生化合物可用于预防和/或治疗糖尿病I型、糖尿病II型、结核病和其他传染病、增殖性疾病、癌症、神经退行性疾病、肥胖症、认知功能障碍和代谢综合征。